Clinical characteristics of the patients included in the study
Patient no. . | CD4 cell count/mm3 . | Treatment . |
---|---|---|
1 | 887 | AZT-3TC-EFV |
2 | 566 | ddl-3TC-EFV |
3 | 625 | AZT-3TC-EFV |
4 | 593 | D4T-3TC-NFV |
5 | 974 | D4T-3TC-NFV |
6 | 626 | AZT-3TC-NFV |
7 | 1285 | D4T-3TC-NVP |
8 | 555 | ddl-TDF-LPV |
9 | 607 | AZT-3TC-EFV |
10 | 638 | AZT-3TC-NFV |
11 | 518 | AZT-3TC-ABC-LPV |
12 | 505 | 3TC-NVP-TDF |
13 | 518 | AZT-3TC-ABC-LPV |
14 | 664 | AZT-DDI-NVP |
15 | 555 | AZT-3TC-EFV |
Patient no. . | CD4 cell count/mm3 . | Treatment . |
---|---|---|
1 | 887 | AZT-3TC-EFV |
2 | 566 | ddl-3TC-EFV |
3 | 625 | AZT-3TC-EFV |
4 | 593 | D4T-3TC-NFV |
5 | 974 | D4T-3TC-NFV |
6 | 626 | AZT-3TC-NFV |
7 | 1285 | D4T-3TC-NVP |
8 | 555 | ddl-TDF-LPV |
9 | 607 | AZT-3TC-EFV |
10 | 638 | AZT-3TC-NFV |
11 | 518 | AZT-3TC-ABC-LPV |
12 | 505 | 3TC-NVP-TDF |
13 | 518 | AZT-3TC-ABC-LPV |
14 | 664 | AZT-DDI-NVP |
15 | 555 | AZT-3TC-EFV |
The viral load was less than 50 copies/mL for patients 1 through 15. All patients have received HAART for at least 1 year. AZT indicates zidovudine; 3TC, lamivudine; EFV, efavirenz; ddl, didanosine; D4T, stavudine; NFV, nelfinavir; NVP, nevirapine; TDF, tenofovir; LPV, lopinavir; and ABC, abacavir.